US2004072726A1PendingUtilityA1

Decoy-containing pharmaceutical compositions and method of using the same

47
Priority: Feb 1, 2002Filed: Feb 1, 2002Published: Apr 15, 2004
Est. expiryFeb 1, 2022(expired)· nominal 20-yr term from priority
Inventors:Ryuichi MorishitaMotokuni AokiToshio OgiharaTomio Kawasaki
A61P 9/14A61P 37/08A61P 35/00A61P 43/00A61P 9/10A61P 9/00A61P 27/02A61P 29/00A61K 48/005C12N 15/113A61P 19/02A61P 17/00A61P 17/04A61K 9/127A61K 47/38A61K 48/0008A61P 13/12C12N 2740/13043C12N 2310/13C12N 2710/10343C12N 15/86A61K 31/711A61K 47/10A61K 48/00A61P 19/00A61K 38/1709A61P 11/06A61K 38/08
47
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A pharmaceutical composition is provided for treatment and prevention of a disease caused by expression of a gene controlled by NF-κB or ets. The composition comprises at least one decoy and a pharmaceutically acceptable carrier. The decoy is an NF-κB decoy, an ets decoy, or a chimera decoy of NF-κB and ets. The disease is cerebral aneurysm, cancer, Marfan's syndrome, aortic detachment, post-angioplasty restenosis, chronic articular rheumatism, asthma, atopic dermatitis, nephritis, renal failure, or plaque rupture. The pharmaceutically acceptable carrier may be a hydrophilic polymer.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition for treatment and prevention of a disease caused by expression of a gene controlled by NF-κB or ets, the composition comprising at least one decoy and a pharmaceutically acceptable carrier.  
     
     
         2 . A composition according to  claim 1 , wherein the at least one decoy is an NF-κB decoy.  
     
     
         3 . A composition according to  claim 1 , wherein the at least one decoy is an ets decoy.  
     
     
         4 . A composition according to  claim 1 , wherein the at least one decoy is a chimera decoy of NF-κB and ets.  
     
     
         5 . A composition according to  claim 1 , wherein the disease is cerebral aneurysm, cancer, Marfan's syndrome, aortic detachment, post-angioplasty restenosis, chronic articular rheumatism, asthma, atopic dermatitis, nephritis, renal failure, or plaque rupture.  
     
     
         6 . A composition according to  claim 1 , wherein the pharmaceutically acceptable carrier is a hydrophilic polymer.

Join the waitlist — get patent alerts

Track US2004072726A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.